Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence

Drug and Alcohol Dependence

Volumn 103, Issue 1-2, 2009, Pages 37-43

  White, Jason ^a   Bell, James ^b   Saunders, John B ^c   Williamson, Paul ^a   Makowska, Maria ^c   Farquharson, Aaron ^a   Beebe, Katherine L ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b South East Sydney and Illawarra Health Services   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Titan Pharmaceuticals   (United States)

Author keywords

Implant; Opioid dependence; Sustained release buprenorphine

Indexed keywords

BUPRENORPHINE; PROBUPHINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; FLUSHING; HEADACHE; HEROIN DEPENDENCE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SORENESS; INJECTION SITE SWELLING; INSOMNIA; LETHARGY; LIMB PAIN; MALE; PALLOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; BUPRENORPHINE; DRUG IMPLANTS; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; PATIENT SELECTION; SAFETY; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 67349126489     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.03.008     Document Type: Article

References (44)

1. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., and Tignol J. French field experience with buprenorphine. Am. J. Addict. 13 Suppl 1 (2004) 17-28
2. Aceijas C., Stimson G.V., Hickman M., and Rhodes T. United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries, Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18 (2004) 2295-2303
3. Ball J.C., Shaffer J.W., and Nurco D.W. The day-to-day criminality of heroin addicts in Baltimore-a study in the continuity of offence rates. Drug Alcohol Depend. 12 (1983) 119-142
4. Bell J., and Burrell T. Retention and attendance with supervised buprenorphine treatment; a case-note review. Drug Alcohol Rev. 25 (2006) 161-165
5. Byrne A., and Wodak A. Data do not support buprenorphine as a first-line treatment for addiction. Am. J. Psychiatry 164 (2007) 11
6. Elkader A., and Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44 (2005) 661-680
7. English D.R., Holman C.D.J., Milne E., Winter M.G., Hulse G.K., Codde J.P., Bower C.I., Corti B., de Clerk N., Kurinczuk J.J., Lewin G.F., and Ryan G.A. The Quantification Of Drug Caused Morbidity And Mortality In Australia. 1995 edition (1995), Commonwealth Department of Human Services and Health, Canberra
8. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., Pezawas L., Aschauer H.N., and Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94 (1999) 1337-1347
9. Gunne L.-M., and Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 7 (1981) 249-256
10. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., and Kanof P.D. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13 (1987) 293-308
11. Hser Y., Anglin M.D., and Powers K. A 24-year follow-up of California narcotics addicts. Arch. Gen. Psychiatry 50 (1993) 577-584
12. Jenkinson R.A., Clark N.C., Fry C.L., and Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 100 (2005) 197-205
13. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Eng. J. Med. 343 (2000) 1290-1297
14. Johnson R.E., Jaffe J.H., and Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267 (1992) 2750-2755
15. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., and Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40 (1995) 17-25
16. Kakko J., Grönbladh L., Svanborg K.D., von Wachenfeldt J., Rück C., Rawlings B., Nilsson L.-H., and Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am. J. Psychiatry 164 (2007) 797-803
17. Kosten T.R., Schottenfeld R., Ziedonis D., and Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181 (1993) 358-364
18. Kuhlman Jr. J.J., Levine B., Johnson R.E., Fudala P.J., and Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93 (1998) 549-559
19. Krupitsky E.M., Zvartau E.E., Lioznov D.A., Tsoy M.V., Egorova V.Y., Belyaeva T.V., Antonova T.V., Brazhenko N.A., Zagdyn Z.M., Verbitskaya E.V., Zorina Y., Karandashova G.F., Slavina T.Y., Grinenko A.Y., Samet J.H., and Woody G.E. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad region Russia. Eur. Addict. Res. 12 (2006) 12-19
20. Landau C.J., Carr W.D., Razzetti A.J., Sessler N.E., Munera C., and Ripa S.R. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin. Ther. 29 (2007) 2179-2193
21. Langendam M.W., van Brussel G.H., Coutinho R.A., and van Ameijden E.J. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am. J. Public Health 91 (2007) 774-780
22. Lanier R.K., Umbricht A., Harrison J.A., Nuwayser E.S., and Bigelow G.E. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction 102 (2007) 1648-1656
23. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., Wesson D.R., Mcnicholas L., Tusel D.J., Malkerneker U., Renner J.A., Santos E., Casadonte P., Pye C., and Stine S. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction 93 (1998) 475-486
24. Ling W., Wesson D.R., Charuvastra C., and Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53 (1996) 401-407
25. Lopatko O.V., White J.M., Huber A., and Ling W. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend. 69 (2003) 317-322
26. Maremmani I., Pani P.P., Pacini M., and Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J. Subst. Abuse Treat. 33 (2007) 91-98
27. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use. HIV risk behavior and criminality: a meta-analysis. Addiction 93 (1998) 515-532
28. Mattick R.P., Kimber J., Breen C., and Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (update of Cochrane Database Syst Rev 2003; (2): CD002207; PMID: 12804429). Cochrane Database Syst. Rev. 3 (2004) CD002207
29. Mattick R.P. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 4 (2002) CD002209
30. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., and Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: an 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 6 (1993) 1049-1055
31. Moss A.R., Vranizan K., Gorter R., Bacchetti P., Watters J., and Osmond D. HIV seroconversion in intravenous drug users in San Francisco 1985-1990. AIDS 8 (1994) 223-231
32. O'Brien C.P., Testa T., O'Brien T.J., Brady J.P., and Wells B. Conditioned narcotic withdrawal in humans. Science 195 (1977) 1000-1002
33. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., and Gessa G.L. Buprenorphine: a controlled clinical trial on the efficacy in the treatment of opioid dependence. Drug Alcohol Depend. 60 (2000) 39-50
34. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., and Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62 (2001) 97-104
35. Puigdollers E., Domingo-Salvany A., Brugal M.T., Torrens M., Alvaros J., Castillo C., Magri N., Martin S., and Vazquez J.M. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst. Use Misuse 39 (2004) 1353-1368
36. Sigmon S.C., Moody D.E., Nuwayser E.S., and Bigelow G.E. An injection depot formulation of buprenorphine extended biodelivery and effects. Addiction 101 (2006) 420-432
37. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat. Med. 20 Suppl 1 (2006) 25-30
38. Sobel B.F., Sigmon S.C., Walsh S.L., Johnson R.E., Liebson I.A., Nuwayser E.S., Kerrigan J.H., and Bigelow G.E. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. 73 (2004) 11-22
39. Strain E.C., Stitzer M.L., and Liebson I.A. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry 151 (1994) 1025-1030
40. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis and addiction severity index. J. Clin. Psychopharmacol. 16 (1996) 58-67
41. Strang J. Abuse of buprenorphine. Lancet 2 (1985) 725
42. Substance Abuse and Mental Health Services Administration, 2007. Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD.
43. Uehlinger C., Deglon J.J., Livoti S., Petitjean S., Waldvogel D., and Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur. Addict. Res. 4 Suppl 1 (1998) 13-18
44. United Nations Office on Drug and Crime. World Drug Report, 2007. Available at: www.unodc.org. Accessed February 10, 2008.